News & Events about Procept Biorobotics.
5-Year results from WATER II when combined with 5-year results from the original WATER study demonstrate that Aquablation therapy provides long-termsymptom relief while preserving sexual function for patients with small and large prostates.The study concluded that Aquablation therapy: Is safe, ...
PROCEPT BioRobotics Co. (NASDAQ:PRCT Get Rating) has received an average recommendation of Moderate Buy from the nine analysts that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold rating and six have given a buy ...
PROCEPT BioRobotics to Report Fourth Quarter and Fiscal Year 2022 Financial Results on February 28, 2023REDWOOD CITY, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the Company), a surgical robotics company focused on advancing patient care by developing ...
Latest Ratings for PRCT
DateFirmActionFromTo Mar 2022B of A SecuritiesMaintainsBuy Mar 2022SVB LeerinkMaintainsOutperform Nov 2021SVB LeerinkMaintainsOutperform
View More Analyst Ratings for PRCT
View the Latest Analyst Ratings
read more...
REDWOOD CITY, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation(Nasdaq: PRCT) (the Company), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that it has entered into a new five-year $52 million ...